Fairmount Funds Management LLC
WEST CONSHOHOCKEN, PA · CIK 1802528 · 13F filing filed 2022-08-15
SEC-registered investment adviser since 2019 · limited liability company
- Assets managed$5.8bn
- Staff30 · 12 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds6 (1 hedge) · $5.9bn gross assets
- Websitefairmountfunds.com
- Form ADV · 2026-08-07SEC adviser record
- Legal entityFAIRMOUNT FUNDS MANAGEMENT LLC (US)
- Kindhedge funds, private equity
- Others nearbyConshohocken, PA, New York, NY, Philadelphia, PA
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 5
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| West Conshohocken, PA (main office)United States | about 12 |
| New York, NYUnited States | |
| Philadelphia, PAUnited States |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| BIOHAVEN PHARMACTL HLDG CO L BHVN | $38.5m8.81% | Added +24.9k |
| AXSOME THERAPEUTICS INC AXSM | $36.1m8.26% | Unchanged |
| BIOCRYST PHARMACEUTICALS INC BCRX | $35.4m8.10% | New |
| GLOBAL BLOOD THERAPEUTICS IN GBT | $30.5m6.97% | Reduced -228.9k |
| ARGENX SE ARGX | $27.9m6.38% | Reduced -50.7k |
| NEUROCRINE BIOSCIENCES INC NBIX | $27.6m6.31% | New |
| INSMED INC INSM | $26.2m5.99% | Reduced -622.4k |
| COGENT BIOSCIENCES INC COGT | $24.9m5.70% | Added +1.2m |
| NUVALENT INC COM | $23.3m5.32% | Added +377.1k |
| ENANTA PHARMACEUTICALS INC ENTA | $22.2m5.08% | Unchanged |
| BEIGENE LTD ONC | $18.0m4.13% | New |
| CTI BIOPHARMA CORP COM | $13.4m3.07% | New |
| POINT BIOPHARMA GLOBAL INC COM | $12.5m2.86% | Reduced -478.6k |
| DBV TECHNOLOGIES S A SPONSORED ADR | $12.3m2.82% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $10.9m2.50% | Unchanged |
| ANNEXON INC ANNX | $10.9m2.50% | Added +1.6m |
| OLEMA PHARMACEUTICALS INC OLMA | $10.9m2.49% | Unchanged |
| ACADIA PHARMACEUTICALS INC ACAD | $10.6m2.42% | Reduced -405.0k |
| TYRA BIOSCIENCES INC TYRA | $10.1m2.32% | Added +132.0k |
| AMARIN CORP PLC SPONS ADR NEW | $8.3m1.90% | Added +1.5m |
| KEROS THERAPEUTICS INC KROS | $7.5m1.72% | Reduced -124.4k |
| TREVI THERAPEUTICS INC TRVI | $4.6m1.04% | New |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $4.3m0.98% | Unchanged |
| VERONA PHARMA PLC VRNA | $3.9m0.89% | Unchanged |
| INSTIL BIO INC COM | $3.1m0.71% | Unchanged |
| ASTRIA THERAPEUTICS INC CATB | $2.7m0.63% | Unchanged |
| ALLAKOS INC ALLKG | $461.0k0.11% | Unchanged |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| PROTAGONIST THERAPEUTICS INC PTGX | $13.0m550.0k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| ALAUNOS THERAPEUTICS INC TCRT · 13D · filed 2026-10-15 | 20.0%≈ $1.3m |
| JADE BIOSCIENCES INC JBIO · 13D · filed 2026-06-09 | 20.0%≈ $310.7m |
| DAMORA THERAPEUTICS INC 13D · filed 2026-02-11 | 20.0%≈ $226.6m |
| ORUKA THERAPEUTICS INC ORKA · 13D · filed 2026-07-01 | 19.5%≈ $1.4bn |
| CRESCENT BIOPHARMA INC. CBIO · 13D · filed 2026-07-20 | 16.5%≈ $118.8m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13D · filed 2026-05-13 | 14.0%≈ $316.0m |
| SPYRE THERAPEUTICS INC SYRE · 13D · filed 2026-10-09 | 10.0%≈ $860.2m |
| INHIBIKASE THERAPEUTICS INC IKT · 13G · filed 2026-02-17 | 9.9%≈ $25.3m |
| COGENT BIOSCIENCES INC COGT · 13D · filed 2026-03-31 | 8.6%≈ $594.3m |
Trades reported as a company insider in Q2 2022
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2022-06-16 | COGENT BIOSCIENCES INC 10% owner · Fairmount Healthcare Fund II LP | Bought | $9.9m1.2m shares |